Skip to content

The effects of drugs on migraine

Comparison of effectiveness of venlafaxine with nortriptyline in migraine prophylaxis

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
IRCT
Registry ID
IRCT2015091524041N1
Enrollment
120
Registered
2016-03-20
Start date
2013-03-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

migrain. common migrain

Interventions

Intervention 1: In the control group: oral medication nortriptyline(tablet) 25 mg once a day for a month(Made in Abidi Company). Intervention 2: In the intervention group: oral medication venlafaxine(
Treatment - Drugs
In the control group: oral medication nortriptyline(tablet) 25 mg once a day for a month(Made in Abidi Company)
In the intervention group: oral medication venlafaxine(Tablet) 37.5 mg dose twice a day for one month.(made in Abidi Company)

Sponsors

Vice Chancellor for research of Tehran Azad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with migraine that they did not receive other drugs in the past two months. Exclusion criteria: The incidence of major complications (side effects that need to cut the treatment, if they happened)

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Frequency of Migraine headache. Timepoint: Before the intervention,one month after intervention. Method of measurement: Questionnaire.;Intensity of Migraine headache. Timepoint: Before the intervention,one month after intervention. Method of measurement: Questionnaire.;Duration of Migraine headache. Timepoint: Before the intervention,one month after intervention. Method of measurement: Questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNima Mohsenzadeh Kermani

Islamic Azad University Tehran Medical Branch

nmohsenzadeh@iautmu.ac.ir; saloome.shahmirzadi@yahoo.com; saloome.shahmirzadi@gmail.com+98 21 2258 5621

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026